Drug Patents owned by Akorn

1. Drug name - AKTEN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8759401 AKORN Aqueous gel formulation and method for inducing topical anesthesia
Jul, 2026

(3 years from now)

Drugs and Companies using LIDOCAINE HYDROCHLORIDE ingredient

Market Authorisation Date: 07 October, 2008

Treatment: Method of inducing topical anesthesia in the eye

Dosage: GEL;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
3.5% GEL;OPHTHALMIC Prescription

2. Drug name - ZIOPTAN

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US5886035 AKORN Difluoroprostaglandin derivatives and their use
Dec, 2022

(7 days from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10864159 AKORN Method and composition for treating ocular hypertension and glaucoma
May, 2029

(6 years from now)

US9999593 AKORN Method and composition for treating ocular hypertension and glaucoma
May, 2029

(6 years from now)

Drugs and Companies using TAFLUPROST ingredient

Market Authorisation Date: 10 February, 2012

Treatment: Reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.0015% SOLUTION/DROPS;OPHTHALMIC Prescription

availability in other generic markets.

Click on the highlighted region to filter.

Other things you might be interested in